ESGO 2024 congress, March 7-10, 2024, in Barcelona, Spain, Europe's largest Gynaecological Oncology gathering, celebrates over 40 years of excellence with the best minds and legends in the field

Industry Supported Sessions

THURSDAY, OCTOBER 27, 2022

12:30-13:30 Hall Alpha 5+6

ESGO Colloquium

Supported by Eisai & MSD

The Colloquium is organised by ESGO and supported by the industry, however the industry has no influence on the content of the programme or speaker selection.

ADVANCES IN ENDOMETRIAL CANCER

Chair: Nicole Concin (Austria/Germany)

Speakers:

The importance of the molecular classification as predictive factor in endometrial carcinoma: Carien Creutzberg (Netherlands)

The role of IO in in first-line endometrial cancer: Toon Van Gorp (Belgium)

The role of TKI’s in second-line recurrent endometrial cancer (lenvatinib, selinexor): Jose Alejandro Pérez-Fidalgo (Spain)

12:30-13:30 Hall Alpha 3+4

Industry symposium 1

Supported by Novocure

NEW PERSPECTIVES IN PLATINUM-RESISTANT OVARIAN CANCER:

TT FIELDS AND UPCOMING THERAPIES

Chairs: Jalid Sehouli (Germany) and Ignace Vergote (Belgium)

Speakers: Susana Banerjee (UK), Isabelle Ray-Coquard (France), David Cibula (Czech Republic), and Martin Glas (Germany)

FRIDAY, OCTOBER 28, 2022

07:30-08:30 Hall Alpha 3+4

Industry symposium 2

Supported by Mersana

ANTIBODY DRUG CONJUGATES IN TREATING PLATINUM-SENSITIVE OVARIAN CANCER: OPTIONS BEYOND PARPI

Chair: Mansoor Raza Mirza (Denmark)

Speakers: Susana Banerjee (UK), Philipp Harter (Germany), Antonio Gonzalez Martin (Spain)

12:30-13:30 Hall Aplha 5+6

Industry symposium 3

Supported by AstraZeneca

LONG-TERM SURVIVAL FOR PATIENTS WITH NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER:

WHAT IS THE GOAL, AND HOW CAN IT BE REACHED?

Chair: Ana Oaknin (Spain)

Speakers: Kathleen Moore (USA), Jonathan Ledermann (UK)

12:30-13:30 Hall Alpha 3+4

Industry symposium 4

Supported by MSD

EMERGING IO LANDSCAPE IN GYNECOLOGICAL CANCERS: ROLE OF BIOMARKER TESTING AND MDT APPROACHES

Chair: Domenica Lorusso (Italy)

Speaker: Hans Ulrich Schildhaus (Germany)

14:40-15:40 Hall Alpha 3+4

Industry symposium 5

Supported by GSK

NEW ERA OF IMMUNE CHECKPOINT INHIBITORS IN ENDOMETRIAL CANCER

Chair: Jalid Sehouli (Germany)

Speakers: Mansoor Mirza (Denmark), Lucy Gilbert (Canada), Christian Marth (Austria)

SATURDAY, OCTOBER 29, 2022

11:00-12:00 Hall Alpha 8

Industry symposium 6

Supported by GSK

CONVERSATIONS AND CONTROVERSIES IN FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED OVARIAN CANCER

Chair: Philipp Harter (Germany)

Speakers: Antonio González Martín (Spain), Toon Van Gorp (Netherlands)

11:00-12:00 Hall Alpha 5+6

Industry symposium 7

Supported by Seagen

PARADIGM SHIFT IN RECURRENT/METASTATIC CERVICAL CANCER? WHAT TO EXPECT AND WHAT TO LOOK FOR?

Chair: Ignace Vergote (Belgium)

Speakers: Isabelle Ray-Coquard (France), David Cibula (Czech Republic), Domenica Lorusso (Italy), Ana Oaknin (Spain), Linn Wölber (Germany)

11:00-12:00 Hall Alpha 3+4

Industry symposium 8

Supported by Intuitive

INTEGRATION OF ROBOTIC-ASSISTED SURGERY IN YOUR GYO PROGRAM

Chair: Ane Gerda Eriksson (Norway)

Speakers: Jan Persson (Sweden), Philippe Van Trappen (Netherlands), Ingolf Juhasz-Böss (Germany)

15:10-15:25 Cinema viewing in Exhibition Hall

Product theatre

Supported by Illumina

A POWERFUL COMBINATION FOR HRD ANALYSIS

Speaker: Bert de Boer (Netherlands)

ESGO 2024 Congress

> View Key Reasons to Attend

Join us in Barcelona

ESGO 2024 Congress

> View Key Reasons to Attend

Join us in Barcelona

ESGO 2024 Congress

> View Key Reasons to Attend

Join us in Barcelona

ESGO 2024 Congress

> View Key Reasons to Attend

Join us in Barcelona

ESGO 2024 Congress

> View Key Reasons to Attend

Join us in Barcelona

Industry Supported Sessions

THURSDAY, OCTOBER 27, 2022

12:30-13:30 Hall Alpha 5+6

ADVANCES IN ENDOMETRIAL CANCER

12:30-13:30 Hall Alpha 3+4

NEW PERSPECTIVES IN PLATINUM-RESISTANT OVARIAN CANCER:

TT FIELDS AND UPCOMING THERAPIES

FRIDAY, OCTOBER 28, 2022

07:30-08:30 Hall Alpha 3+4

ANTIBODY DRUG CONJUGATES IN TREATING PLATINUM-SENSITIVE OVARIAN CANCER: OPTIONS BEYOND PARPI

12:30-13:30 Hall Aplha 5+6

LONG-TERM SURVIVAL FOR PATIENTS WITH NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER:

WHAT IS THE GOAL, AND HOW CAN IT BE REACHED?

12:30-13:30 Hall Alpha 3+4

EMERGING IO LANDSCAPE IN GYNECOLOGICAL CANCERS: ROLE OF BIOMARKER TESTING AND MDT APPROACHES

14:40-15:40 Hall Alpha 3+4

NEW ERA OF IMMUNE CHECKPOINT INHIBITORS IN ENDOMETRIAL CANCER

SATURDAY, OCTOBER 29, 2022

11:00-12:00 Hall Alpha 8

CONVERSATIONS AND CONTROVERSIES IN FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED OVARIAN CANCER

11:00-12:00 Hall Alpha 5+6

PARADIGM SHIFT IN RECURRENT/METASTATIC CERVICAL CANCER? WHAT TO EXPECT AND WHAT TO LOOK FOR?

11:00-12:00 Hall Alpha 3+4

INTEGRATION OF ROBOTIC-ASSISTED SURGERY IN YOUR GYO PROGRAM

15:10-15:25 Cinema viewing in Exhibition Hall

A POWERFUL COMBINATION FOR HRD ANALYSIS

Directly to:

ESGO Congress Newsletter

You may also like

Reasons to Attend

ESGO 2024

Photo Gallery

Registration

ESGO 2024 Congress

Why Attend

Scientific Info

Congress Info

About

News Updates